Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.37 |
| ▸ | MYC | P01106 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561071 | 0.89 | P4HTM (0.35) | P4HTMSCN9AMYCNLRP3 | |
| SCHEMBL1098645 | 0.67 | SCN9A (0.50) | P4HTMSCN9AMYCPTPN1SCN3A | |
| SCHEMBL22097500 | 0.67 | P4HTM (0.36) | P4HTMSCN9AMYCCA2PTPN1 | |
| SCHEMBL27253156 | 0.66 | CA2 (0.47) | P4HTMSCN9AMYCCA2 | |
| SCHEMBL364110 | 0.65 | HDAC3 (0.58) | P4HTMSCN9AMYCPTPN1SCN3A | |
| Hydrochloric Acid SCHEMBL4438185 | 0.64 | P4HTM (0.56) | P4HTMSCN9AMYCPTPN1SCN3A | |
| SCHEMBL695182 | 0.64 | — | — | |
| SCHEMBL208791 | 0.64 | — | — | |
| SCHEMBL20446653 | 0.64 | — | — | |
| SCHEMBL14642791 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | claimed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | claimed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | P4HTM 2243/4885SCN9A 4629/4885MYC 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.